Loading...
•
Mar 31, 2023
Rigel Q1 2023 Earnings Report
Reported strong first quarter with increased net product sales and advanced launch of REZLIDHIA.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $13.5 million for the first quarter of 2023, with total revenues of $26.1 million. The company saw a 47% increase in net product sales compared to Q1 2022, driven by TAVALISSE and REZLIDHIA sales.
Net product sales increased by 47% compared to Q1 2022.
TAVALISSE net product sales increased by 38% from the same period in 2022, reaching $22.3 million.
REZLIDHIA net product sales were $1.5 million.
Net loss decreased to $13.5 million, compared to a net loss of $27.4 million for the same period of 2022.
Forward Guidance
Rigel has established a strong foundation for its hematology-oncology business to successfully deliver growth in both TAVALISSE and REZLIDHIA, and to advance its development programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...